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It has been proposed that the hexosamine pathway acts as a
nutrient-sensing pathway, protecting the cell against abun-
dant fuel supply, and that accumulation of hexosamines rep-
resents a biochemical mechanism by which hyperglycemia
and hyperlipidemia induce insulin resistance. We hypothe-
sized that if an increased flux through the hexosamine path-
way caused insulin resistance in humans, the hexosamine lev-
els should be increased in adipose and/or muscle tissue in
insulin-resistant subjects, such as patients with type 2 diabe-
tes and obese individuals. In addition, we reasoned that if the
hexosamine pathway were a nutrient-sensing pathway, hex-
osamine levels in adipose and skeletal muscle tissue should be
correlated with levels of circulating nutrients, such as glucose
and free fatty acids (FFAs) and leptin concentrations.
In a human cross-sectional study of 55 patients [20 with type
2 diabetes mellitus (DM) and 21 normal-lean (NL) and 14 nor-
mal-obese (NO) subjects] who underwent hip replacement
surgery, adipose and muscle tissue biopsies were obtained
and analyzed for levels of hexosamines [UDP-N-acetylglu-
cosamine (UDP-GlcNAc) and UDP-N-acetylgalactosamine]
and hexoses (UDP-glucose and UDP-galactose). Fasting
plasma glucose, glycosylated hemoglobin, serum insulin and
homeostasis model assessment calculations, serum lipids, and
leptin were measured on the same day.
Hexosamines were not elevated in adipose and muscle tis-
sue of patients with type 2 DM compared with NL and NO
subjects (UDP-GlcNac DM vs. NL vs. NO, 3.3  2.3 vs. 2.2  2.1
vs. 3.0 2.0 nmol/g tissue in adipose tissue and 8.1 2.9 vs. 7.8
2.8 vs. 7.6  2.8 nmol/g tissue in muscle tissue, respectively).
Hexosamines in adipose tissue were positively correlated
with circulating levels of FFA (UDP-GlcNAc, r 0.33, P < 0.05;
UDP-N-acetylgalactosamine, r 0.41, P < 0.01). Adipose tissue
UDP-GlcNAc was correlated with leptin levels (r  0.33; P <
0.05). No such relationship was identified in muscle tissue.
In conclusion, these findings argue against a pathophysi-
ological role of the hexosamine pathway in insulin resistance
in humans but support the hypothesis that the hexosamine
pathway in adipose tissue, not in muscle, is a FFA-sensing
pathway and could be involved in the regulation of leptin
expression. (J Clin Endocrinol Metab 89: 5132–5137, 2004)
THE PATHOGENESIS OF insulin resistance, a centralfeature of type 2 diabetes mellitus (DM), is complex
and incompletely understood, but environmental factors in-
cluding excess nutrients and obesity play a major role. Once
diabetes exists, both chronic hyperglycemia and hyperlip-
idemia further aggravate the already impaired action and
secretion of insulin. These adverse metabolic consequences
of chronic hyperglycemia and hyperlipidemia have been
conceptualized as glucose toxicity (1), and lipotoxicity (2).
It has been suggested that accumulation of products of the
hexosamine biosynthetic pathway represents a biochemical
mechanism by which hyperglycemia and hyperlipidemia
induce insulin resistance (3, 4). Glutamine fructose-6-phos-
phate amidotransferase (GFAT) is the key enzyme of this
pathway, using the amide group of glutamine to convert
fructose 6-phosphate to glucosamine-6-phosphate (5, 6).
Glucosamine-6-phosphate is then converted to UDP-hex-
osamines, i.e. UDP-N-acetylglucosamine (UDP-GlcNAc) and
UDP-N-acetylgalactosamine (UDP-GalNAc).
Indeed, animal studies show that hyperglycemia in rats
with streptozotocin-induced diabetes (7), hyperglycemia in-
duced by glucose or somatostatin infusion in normal rats (7,
8), prolonged elevations in serum free fatty acids (FFAs)
induced by lipid infusion (8), and high-fat feeding in normal
rats (9) all result in increased muscle UDP-hexosamines (as
a result of an increased flux of fructose-6-phosphate into the
hexosamine pathway), as well as in insulin resistance, as
demonstrated by euglycemic-hyperinsulinemic clamp stud-
ies (8, 9). Furthermore, in normal rats, it has been found that
hyperglycemia or hyperlipidemia not only cause increased
muscle UDP-GlcNAc levels and insulin resistance (8) but
also result in increased leptin mRNA levels in fat and skeletal
muscle and in increased serum leptin concentrations (10).
Based on these observations, the hexosamine pathway has
been proposed as a nutrient-sensing pathway (10).
Human studies focused on the hexosamine pathway are
scarce. We hypothesized that if an increased flux through the
hexosamine pathway caused insulin resistance in humans,
the levels of the stable metabolites of the hexosamine path-
way, UDP-GlcNAc and UDP-GalNAc, should be increased
in adipose and/or muscle tissue in disease states character-
ized by insulin resistance; for example, in patients with type
2 DM or in obese subjects. To test this hypothesis, we mea-
Abbreviations: BMI, Body mass index; CV, coefficient(s) of variation;
DM, diabetes mellitus; FFA, free fatty acid; GFAT, glutamine fructose-
6-phosphate amidotransferase; HbA1c, glycosylated hemoglobin;
HOMAR, homeostasis model assessment; NL, normal-lean; NO, normal-
obese; NS, not significant; UDP-GalNAc, UDP-N-acetylgalactosamine;
UDP-GlcNAc, UDP-N-acetylglucosamine.
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sured UDP-GlcNAc and UDP-GalNAc levels in adipose and
skeletal muscle tissue of patients with type 2 DM and of lean
and obese subjects. In addition, we reasoned that if the hex-
osamine pathway acts as a nutrient-sensing pathway, levels
of UDP-GlcNAc and UDP-GalNAc in adipose and skeletal
muscle tissue should be correlated with levels of circulating
nutrients, like glucose and FFA, and with serum leptin
concentrations.
Subjects and Methods
Subjects
Fifty-five Caucasian patients (female to male ratio of 38:17) who were
referred for elective hip replacement surgery participated in the study.
The study was performed in two hospitals (University Medical Center
Nijmegen and Sint Maartenskliniek Nijmegen, The Netherlands). In-
clusion criteria were an age greater than 30 yr and the ability to give
informed consent. Exclusion criteria were evidence for coagulation dis-
orders and clinical evidence for the presence of other metabolic or
endocrine disorders. All patients provided written informed consent
before participating in the study. The Hospital Ethics Committee ap-
proved the experimental protocol.
All patients referred for surgical hip replacement therapy had os-
teoarthritis. A total of 44 patients had primary osteoarthritis (degener-
ative joint disease), one of whom had osteoarthritis in combination with
polymyalgia rheumatica and one in combination with polymyalgia
rheumatica and osteoporosis. Eleven patients had secondary osteoar-
thritis; in four patients it had been caused by rheumatoid arthritis, in four
patients by congenital dislocation of the hip, in two patients by avascular
necrosis [one after fracture of the femoral neck and one possibly asso-
ciated with low-dose prednisone (5 mg) therapy for rheumatoid arthri-
tis], and in one patient by Legg-Calve´-Perthes disease.
In the whole group, four patients used prednisone, 5 mg once daily,
because of polymyalgia rheumatica, obstructive lung disease, or rheu-
matoid arthritis.
After inclusion in the study, 20 patients were classified as diabetic; 12
of these had a medical history of diabetes, and eight had a fasting plasma
glucose concentration greater than 126 mg/dl (7.0 mmol/liter) (11),
but no previous history of diabetes. The other 35 patients were classified
as nondiabetic. To adjust for differences in body weight between the
diabetic and the nondiabetic patient group, the nondiabetic group was
further divided into lean [body mass index (BMI)  27 kg/m2, normal-
lean (NL) group, n  21] and an obese (BMI  27 kg/m2, normal-obese
(NO) group, n  14) groups.
Protocol
At the day of hip surgery, fasting blood samples were obtained for
measurements of plasma glucose and insulin concentrations, percentage
glycosylated hemoglobin (HbA1c), serum lipid analyses (total choles-
terol, high-density lipoprotein-cholesterol, low-density lipoprotein-cho-
lesterol, triglycerides, and FFAs), and serum leptin levels. Patients un-
derwent regional or general anesthesia; during surgery, they all received
iv fluids consisting of 5% glucose and 0.9% saline (500–1000 ml) followed
by Ringer’s solution.
After incision, adipose and muscle biopsies were taken from the sc
fat at the hip region and from the gluteus maximus muscle, respectively.
After biopsy, all samples were immediately frozen in liquid nitrogen and
stored at 80 C until analysis.
Routine laboratory analyses
Plasma glucose was measured using the glucose oxidation method
(GOD-PAP, Hitachi 747; Roche Molecular Biochemicals, Indianapolis,
IN). Plasma insulin was determined using an in-house RIA [interassay
coefficient of variation (CV), 6%]. Hemoglobin A1c (reference range,
4.8–6.2%) was determined with an HPLC technique (Bio-Rad, Hercules,
CA). Triglycerides (Triglycerides GPO-PAP method), total cholesterol
(Cholesterin CHOD-PAP method), and high-density lipoprotein-cho-
lesterol (after addition of cholesterin precipitation reagents) were all
determined on a Hitachi 747 auto-analyzer, and low-density lipoprotein-
cholesterol was calculated. The concentrations of FFA were analyzed
using an enzymatic method (acyl-CoA-synthetase-acyl-CoA-oxidase,
FFA C-kit, Waco Chemicals, Neuss, Germany). Serum leptin was de-
termined with a commercial human leptin RIA kit (Linco Research Inc.,
St. Louis, MO).
Measurement of UDP-hexosamines and UDP-hexoses
UDP-hexosamines (UDP-GlcNAc and UDP-GalNAc) and UDP-hex-
oses (UDP-glucose and UDP-galactose) were quantitated using an
HPLC-based assay, suitable for application in small samples of human
adipose and muscle tissue, as earlier described (12). For UDP-GlcNAc,
intra- and interassay CVs were less than 6%. For UDP-GalNAc, the
intraassay CV was 5.4% and the interassay CV was less than 13%. For
UDP-glucose and UDP-galactose, the intraassay CV were less than 6.5%
and the interassay CV was less than 7%. The limit of detection for all
metabolites (UDP-GlcNAc, UDP-GalNAc, UDP-glucose, and UDP-ga-
lactose) in muscle and in adipose tissue was 0.6 nmol/g tissue (12).
Calculations
Insulin resistance was calculated using homeostasis model assess-
ment (HOMAR) [(fasting insulin in milliunits per liter fasting glucose
in millimoles/liter)/22.5] (13).
Data presentation and statistical analysis
To test differences between two groups, the unpaired Student’s t test
was used. Differences between more than two study groups were tested
using one-way ANOVA in case of normal distributions and the Kruskall-
Wallis test in case of nonnormal distributions. If statistically significant
differences were identified, least significant difference post hoc analysis
was performed in case of normal distributions. Correlations were cal-
culated by Spearman’s ranks method. For all statistical analyses, the
SPSS software package 10.0 (SPSS, Inc., Chicago, IL) was used. P  0.05
was considered statistically significant. Results are given as mean sd.
Results
Patients
Baseline characteristics of the three groups [DM (n  20),
NL (n  21), and NO (n  14)] are described in Table 1. In
DM, the 12 patients with a previous history of diabetes were
known to have the disease for 12 yr (range, 1–35 yr). They
were treated with diet (n  3), sulfonylureas (n  3), met-
formin (n 1), the combination sulfonylurea and metformin
(n 1), metformin and insulin (n 1), or with insulin alone
(n  3). Of the eight patients with an abnormal fasting glu-
cose level but no history of diabetes, one used prednisone for
obstructive lung disease and one had a medical history of
gestational diabetes. Of those classified as nondiabetic, four
subjects had a fasting glucose level greater than 110 but less
than 126 mg/dl (6.1 but 7.0 mmol/liter); none of these
subjects had a history of diabetes or had symptoms of hy-
perglycemia, and all had normal HbA1c levels.
Groups differed significantly with respect to plasma glu-
cose and insulin levels, HbA1c, HOMAR, BMI, and serum
leptin levels (ANOVA, all P  0.05). Post hoc analyses re-
vealed that the diabetic group had significantly higher
plasma glucose and insulin concentrations, higher HOMAR
values, and higher HbA1c percentages, compared with the
NL and NO group (Table 1). The DM group had significantly
higher BMI (29 5.2 vs. 25 3.7 kg/m2, P 0.005) and leptin
levels (26  22 vs. 11  7 ng/ml, P  0.05) compared with
the NL group; BMI and leptin levels were similar between the
DM and NO group (Table 1). Age and lipid levels were not
significantly different among the three groups.
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Comparison of hexosamines and hexoses in adipose and
muscle tissues
In Table 2 hexosamine (UDP-GlcNAc and UDP-GalNAc)
and hexose (UDP-glucose and UDP-galactose) levels in both
adipose and skeletal muscle tissue are presented. No signif-
icant differences in hexosamine levels in either adipose or
muscle tissue were observed among the three different study
groups. Also, when the DM group was compared with the
whole nondiabetic group (NL and NO subjects), UDP-hex-
osamines were similar [DM group vs. nondiabetic groups:
adipose tissue, UDP-GlcNAc, 3.3  2.3 vs. 2.6  2.1; UDP-
GalNAc, 0.74  0.71 vs. 0.75  0.70 nmol/g tissue; muscle
tissue, UDP-GlcNAc, 8.1  2.9 vs. 7.7  2.8, UDP-GalNAc,
4.7 1.4 vs. 4.6 1.1 nmol/g tissue, P not significant (NS)
for all comparisons]. Finally, when the DM and obese groups
were combined and compared with NL subjects, again, sim-
ilar results were obtained (DM  obese vs. NL, adipose
tissue, UDP-GlcNAc, 3.2  2.1 vs. 2.2  2.1; UDP-GalNAc,
0.86  0.74 vs. 0.55  0.53 nmol/g tissue; muscle tissue,
UDP-GlcNAc, 7.9 2.8 vs. 7.8 2.8; UDP-GalNAc, 4.7 1.3
vs. 4.6  1.1 nmol/g tissue, P  NS for all comparisons).
No statistically significant differences in hexose levels in
either adipose or muscle tissue were observed among the
three different study groups (ANOVA). Again, when the
diabetic patient group was compared with the whole non-
diabetic group (NL and NO subjects), UDP-glucose levels in
muscle were comparable (DM group, 16 11 vs. nondiabetic
groups, 20  10 nmol/g tissue, P  NS).
No significant correlations were found between fasting
plasma insulin concentrations or HOMAR on the one hand
and UDP-GlcNAc and UDP-GalNAc concentrations in adi-
pose and muscle tissues on the other hand.
Correlations between UDP-GlcNAc and UDP-GalNAc in
adipose and muscle tissue and fasting glucose, FFA, and
leptin concentration
No correlations were found between fasting plasma glu-
cose levels and UDP-GlcNAc and UDP-GalNAc concentra-
tions in adipose and muscle tissues, neither in the total group
of patients (n  55) nor in the nondiabetic group (n  35).
There was a positive correlation between adipose tissue
UDP-GlcNAc concentration and plasma FFA level (r 0.33;
P 0.05; n 55). This correlation was even stronger between
adipose tissue UDP-GalNAc concentrations and plasma FFA
levels (r  0.41; P  0.01; n  55). If diabetic patients were
excluded from this analysis, similar results for the correlation
between adipose tissue UDP-GlcNAc concentration and
plasma FFA level were obtained (r 0.44; P  0.05; n  35),
whereas there was a trend between adipose tissue UDP-
GalNAc concentrations and plasma FFA levels (r 0.37; P
0.06; n  35) (Fig. 1). No correlation was found between
muscle tissue UDP-GlcNAc concentration and plasma FFA
level (r  0.06; P  NS; n  55), nor between muscle tissue
UDP-GalNAc concentration and plasma FFA levels (r 
0.01; P  NS; n  55). Plasma leptin levels were positively
correlated with adipose tissue UDP-GlcNAc concentrations
(r  0.33; P  0.05; n  55), but not with muscle tissue
UDP-GlcNAc concentrations (r  0.04; P  NS; n  55).
When diabetic and nondiabetic patients were analyzed sep-
arately, the correlation no longer reached statistical signifi-
cance (diabetic patients, r  0.05, P  NS, n  20; nondi-
abetic subjects, r 0.29, PNS, n 35). Plasma leptin levels
did not correlate with adipose or muscle tissue UDP-GalNAc
concentrations (r  0.20 and 0.09, respectively; P  NS;
n  55).
Discussion
Two main conclusions can be drawn from this cross-sec-
tional study. First, levels of stable hexosamine pathway end-
products are not increased in adipose and muscle tissue of
patients that are characterized by insulin resistance, and
there was no correlation between hexosamine levels and
parameters associated with insulin resistance. Second, hex-
osamine levels in adipose tissue, but not in muscle, are cor-
TABLE 1. Baseline characteristics (mean  SD) of the diabetic,
NL, and NO groups
Diabetic patients
Nondiabetic patients
NL NO
No. 20 21 14
Gender (F/M) 16/4 13/8 9/5
Osteoarthritis
(primary/secondary)
17/3 16/5 11/3
Age (yr) 68  11 69  11 68  10
BMI (kg/m2) 29  5.2a 24  3.3 31  3.8
Waist/hip ratio 0.93  0.10 0.90  0.08 0.97  0.10
FPG (mmol/liter) 9.4  2.3c,f 5.3  0.6 5.6  0.7
FPG (mg/dl) 170  41c,f 95  11 100  13
Insulin (pmol/liter) 139  62a,d 90  54 90  38
HOMAR 8  3
c,f 2.6  1.1 2.8  1.1
HbA1c (%) 6.6  1.5
b,e 5.4  0.4 5.5  0.6
Cholesterol (mg/dl) 197  35 201  39 217  43
HDL-Chol (mg/dl) 43  19 54  12 46  15
LDL-Chol (mg/dl) 124  27 128  35 143  46
Triglycerides (mg/dl) 151  71 115  53 168  124
FFA (mmol/liter) 0.58  0.40 0.64  0.25 0.78  0.22
Leptin (ng/mliter) 26  22a 11  7 23  14
F, Female; M, male; HDL-Chol, high-density lipoprotein choles-
terol; LDL-Chol, low-density lipoprotein cholesterol.
To convert to SI units: insulin, multiply by 0.1442 to obtain mil-
liunits per liter; triglycerides, multiply by 0.01129 to obtain milli-
moles per liter; cholesterol, HDL-Chol, and LDL-Chol, multiply by
0.02586 to obtain millimoles per liter.
a P 0.005, b P 0.001, c P 0.000: diabetic group vs. normal-lean.
d P 0.05, e P 0.010, f P 0.000: diabetic group vs. normal-obese.
TABLE 2. UDP-GlcNAc, UDP-GalNAc, UDP-glucose, and UDP-
galactose concentrations in adipose and muscle tissue in the
diabetic, NL, and NO groups
Diabetic
patients NL NO
Adipose tissue
(nmol/g tissue)
UDP-GlcNAc 3.3  2.3 2.2  2.1 3.0  2.0
UDP-GalNAc 0.74  0.71 0.55  0.53 0.97  0.80
UDP-Glucose 2.5  2.2 1.7  1.3 3.1  3.0
UDP-Galactose 0.28  0.50 0.35  0.34 0.72  0.84
Muscle tissue
(nmol/g tissue)
UDP-GlcNAc 8.1  2.9 7.8  2.8 7.6  2.8
UDP-GalNAc 4.7  1.4 4.6  1.1 4.6  1.2
UDP-Glucose 16  11 18  11 23  7
UDP-Galactose 1.7  1.4 1.8  1.3 2.0  1.1
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related with circulating FFA and leptin levels. All together,
these findings argue against involvement of the hexosamine
pathway in insulin resistance in humans but support the
concept that the hexosamine pathway in adipose tissue, not
in muscle, can act as a FFA-sensing pathway and could be
involved in the regulation of leptin expression.
The first conclusion is based on the finding that the tissue
concentrations of UDP-GlcNAc and UDP-GalNAc, which
represent the stable end products of the hexosamine path-
way, were similar in our three different study groups. The
diabetic and the nondiabetic obese groups are by definition
characterized by insulin resistance, which is also reflected by
higher HOMAR values. Also, if the diabetic group was com-
pared with the whole nondiabetic group, similar results were
found. In addition, no correlation at all was found between
parameters of insulin resistance (fasting insulin and HOMAR
values) on the one hand and tissue hexosamine levels on the
other.
Although induction of insulin resistance by activation of
the hexosamine pathway is fairly well documented in ani-
mals (7–9, 14, 15), studies in humans are limited and results
are conflicting with animal studies (16–20). For example,
short-term glucosamine infusion, a reproducible method to
increase the flux through the hexosamine pathway, resulting
in increased hexosamine levels in skeletal muscle tissue in
animals (9, 21, 22), did not affect insulin sensitivity in humans
(18, 19). In patients with type 2 DM, GFAT activity in skeletal
muscle was found to be elevated (17), but inverse correlations
were reported between GFAT activity and glucose disposal
rate (16, 17), which is in contrast with the reported positive
correlation between GFAT activity in adipose (14) and mus-
cle tissue (14, 15) and glucose disposal rate in transgenic
mice. We have reported that in type 2 diabetic patients,
hexosamine levels did not decrease, but even increased in
skeletal muscle, after amelioration of hyperglycemia-
induced insulin resistance (20). Including the results from the
present study, there is a fair amount of human data now that
oppose involvement of (over)activation of the hexosamine
FIG. 1. Correlations between UDP-GlcNAc
(top) and UDP-GalNAc (bottom) in adipose tis-
sue on the one hand and serum FFA concentra-
tions on the other hand in the whole patient
group (n  55). E, Diabetic patients; F, nondi-
abetic subjects.
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biochemical pathway in the pathogenesis of insulin resis-
tance at the level of the skeletal muscle.
Our second conclusion is based on the finding that adipose
(but not muscle) tissue concentrations of UDP-GlcNAc show
a positive correlation with circulating plasma FFA and serum
leptin concentrations. Also, there was a positive correlation
between adipose UDP-GalNAc concentrations and circulat-
ing plasma FFA. These findings are to some extent in agree-
ment with findings in animals, in which an increased fatty
acid metabolism results in increased muscle UDP-GlcNAc
levels and insulin resistance (8, 9) and increased hexosamine
levels in adipose tissue in GFAT transgenic mice result in
increased serum leptin levels and induce leptin gene expres-
sion in adipose and muscle tissue (9, 23), which would be
consistent with a role for the hexosamine pathway as a gen-
eral nutrient-sensing pathway (9). Our finding that hex-
osamine levels in human adipose tissue are correlated with
serum leptin levels also fits with the previously reported
observation that leptin production is regulated by hex-
osamines in human adipose tissue (24). However, we have
not proven per se that hexosamines induce leptin expression
because we do not have data on tissue leptin mRNA or
protein levels from the same samples.
In the present study, we found a positive correlation be-
tween hexosamines in human adipose tissue and serum
FFAs as well as serum leptin, but, in contrast with animal
studies (10), such a relationship did not exist in muscle tissue
(to date, human studies are not reported). As such, our study
provides evidence for the hypothesis that in humans the
hexosamine pathway may serve as a FFA-sensing pathway
in adipocytes and could be involved in the regulation of
leptin expression.
Our study has a number of limitations. Inherent to human
in vivo studies, this cross-sectional study provides only as-
sociative data and does not prove a definite cause and effect
relationship. Nevertheless, the convincing absence of any
relationship between tissue hexosamine metabolites and
measures of insulin resistance, in combination with similar
previous findings in humans, renders a role for the hex-
osamine pathway within the concept of insulin resistance
highly unlikely. Within the study population, eight subjects
had a fasting glucose concentration of greater than 126 mg/dl
(7.0 mmol/liter) but had no prior history of diabetes and
normal HbA1c levels. These patients were classified as hav-
ing diabetes, but one may question whether a fasting glucose
level just before major surgery is really diagnostic for dia-
betes. If data were reanalyzed after exclusion of these pa-
tients, however, the results remained the same (data not
shown).
The indications for total hip replacement surgery, comor-
bidity, and medication used by our subjects might also have
influenced the results. The indication for total hip surgery
was osteoarthritis, the majority being primary degenerative
joint disease. In 11 patients, osteoarthritis was secondary to
other diseases, like congenital dislocation, avascular necro-
sis, or rheumatoid arthritis. Concerning comorbidity, dia-
betic patients have more comorbidity, especially cardiovas-
cular morbidity and hypertension, and comedication
compared with nondiabetic patients, but this is inherent in
this population.
Our study approach, i.e. collection of tissue during sur-
gery, has the advantage that a relatively large tissue sample
can be obtained. However, it also has some limitations, in-
cluding the fact that samples were obtained under anesthe-
sia. In addition, the fasting blood samples were drawn at
least 30 min before the muscle and adipose tissue samples
were taken and before induction of anesthesia was started.
It seems unlikely that this has influenced the results, and
other studies with a similar study design have been reported
(24). Finally, sc fat in the hip region was used to determine
hexosamine metabolite levels, which may differ from the
levels of hexosamines in visceral fat. Nevertheless, metabolic
end-products of the hexosamine pathway have been studied
comprehensively in animals, but in humans, the metabolic
products of this pathway are mainly investigated in skeletal
muscle tissue (16, 17, 20), whereas studies in adipose tissue
(24) are scarce. The present study is the first that investigates
the relation between nutrients (glucose and FFAs) and hex-
osamine concentrations in adipose tissue in vivo and that
quantifies the products of the hexosamine pathway in both
adipose and skeletal muscle tissue simultaneously of the
same patients.
In summary, the levels of hexosamines in fat and muscle
tissue of human subjects that are characterized by insulin
resistance are similar to the levels found in insulin-sensitive
subjects. These findings strongly oppose to a pathophysio-
logical role of the hexosamine pathway in insulin resistance
in humans. Our finding of a relationship between adipose
tissue levels of hexosamines and plasma FFA and serum
leptin levels is in agreement with a role of the hexosamine
pathway as a FFA-sensing pathway, which could be in-
volved in the regulation of leptin expression. Such a rela-
tionship was not identified in muscle tissue. More research
is needed to determine in more detail which role the hex-
osamine pathway plays in intermediate metabolism in
humans.
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